Revenue: As of FY2025 Q1, the actual value is USD 1.637 M.EPS: As of FY2025 Q1, the actual value is USD -0.45.<h3>Segment Revenue</h3><ul><li>Revenue from Government Contract: $1,636,863 for the three-month period ended March 31, 2025, compared to $0 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Research and Development Expenses: $5,354,588 for the three-month period ended March 31, 2025, compared to $4,425,728 for the same period in 2024, representing an increase of $928,860 (21%).</li><li>General and Administrative Expenses: $1,687,445 for the three-month period ended March 31, 2025, compared to $1,457,353 for the same period in 2024, representing an increase of $230,092 (16%).</li><li>Net Loss: $-5,357,651 for the three-month period ended March 31, 2025, compared to $-5,850,132 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $-5,965,680 for the three-month period ended March 31, 2025, compared to $-5,683,730 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: $-16,894 for the three-month period ended March 31, 2025, related to purchases of laboratory equipment.</li><li>Net Cash Provided by Financing Activities: $7,914,402 for the three-month period ended March 31, 2025, related to offerings of common stock and warrants.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: GeoVax plans to advance its differentiated vaccine/immunotherapy technologies, aiming to develop preventive and therapeutic vaccines and immunotherapies against infectious diseases and various cancers. The company intends to advance products through human clinical testing and seek partnership or licensing arrangements for regulatory approval and commercialization.</li><li>Non-Core Business: GeoVax is pursuing additional capital resources through public or private equity or debt financings, government grants/contracts, arrangements with strategic partners, or other sources to continue its planned operations into the third quarter of 2025.</li></ul>

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 1.637 M